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Abstract 
Intravenous iron formulations are a class of complex drugs that are commonly used to treat a wide 
variety of disease states associated with iron deficiency and anemia. Venofer® (iron–sucrose) is one 
of the most frequently used formulations, with more than 90% of dialysis patients in the United States 
receiving this formulation. Emerging data from global markets outside the United States, where many 
iron–sucrose similars or copies are available, have shown that these formulations may have safety and 
efficacy profiles that differ from the reference listed drug. This may be attributable to uncharacterized 
differences in physicochemical characteristics and/or differences in labile iron release. As 
bioequivalence evaluation guidance evolves, clinicians should be educated on these potential clinical 
issues before a switch to the generic formulation is made in the clinical setting. 
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Introduction 
Intravenous (IV) iron formulations provide a clinical treatment option for chronic kidney disease 
(CKD) patients when iron supplementation is required but oral administration is not suitable owing to 
intolerance or lack of efficacy. IV iron use is increasing worldwide, especially in the CKD 
population.
1,2
 More aggressive IV iron use in the CKD population has been driven by several trials 
demonstrating adverse safety signals with erythropoiesis-stimulating agents (ESAs). Increased risk of 
stroke and cardiovascular death and a trend toward higher risk of solid organ cancers were observed 
in these trials, prompting a product label change by the U.S. Food and Drug Administration (FDA).
3–6
 
In 2011, the Centers for Medicare and Medicaid Services instituted a partially capitated payment 
system (i.e., the bundle) for dialysis services, which included both ESAs and IV iron, which were 
previously separately billable.
7
 The recombinant ESA therapies are clearly far more expensive than IV 
iron products, which accelerated a national trend to use larger cumulative doses of IV iron. Doses of 
ESAs began to decline, and IV iron doses began to rise, even several months in advance of bundle 
implementation.
2
 More than 70% of patients receiving chronic hemodialysis receive IV iron, most 
frequently the reference listed drug (RLD) Venofer®  (iron sucrose).
8
 The most common doses 
administered (19%) range from 1.2–2.5 g of elemental iron annually; however, a nearly equal 
proportion of patients (15%) receive 4.8 g or more annually.
8
 The Dialysis Outcomes Practice Patterns 
study reported that mean ferritin increased from  640 to 826 ng/mL from prebundle to postbundle 
(January 2012) and remained stable through December 2013.
8
 The percent reported that ferritin > 
1200 ng/mL, a biomarker of stored iron, increased from 8.6% to 18%.
9
  
Outside the United States, there are a plethora of generic iron–sucrose products (iron–sucrose 
similar (ISS)) on the global market. When compared to the reference listed drug (RLD) Venofer, 
several ISS formulations have been shown in translational models to have significantly more tissue 
iron deposition, induce greater tissue cytokine expression, and cause endothelial dysfunction.
10–12
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Here, I evaluate IV iron in the context of its complex formulations and biodistribution and the factors 
that impart challenges in evaluation of bioequivalence. 
 
Complex chemistry and biodistribution of IV iron formulations create inherent challenges for 
bioequivalence  
Early IV iron compounds were formulated as inorganic iron–oxyhydroxide complexes. With little 
relative protection of the inorganic ferric iron, these formulations were highly toxic, with high 
incidences of severe hypotension.
13
 Current commercially available IV iron formulations consist of an 
iron–oxyhydroxide core surrounded by carbohydrate shells of various sizes and polysaccharide branch 
characteristics.
13,14 
 The size of commercially available IV iron–carbohydrate complexes range from 5 
to 100 nm, and thus meet the definition for nanoparticle formulations.
15
 The manufacture of iron–
carbohydrate complex formulations is highly sensitive to pH, temperature, and other conditions in the 
manufacturing process. This presents significant challenges to reproducible manufacturing, 
characterization, and safety of generic or similar IV iron product production.
 
 
 Iron oxide nanoparticles with magnetic particle cores are well-established magnetic 
resonance imaging (MRI) agents and have been used safely; however, different carbohydrate shell 
structures determine the relative uptake by endothelial and lymphatic cells as well as the by the 
reticuloendothelial system.
15
 The clinical use of iron–carbohydrate nanoparticle formulations has not 
been well studied with regard to potential long-term toxicity beyond immediate labile iron appearance 
and immunogenicity.
15
 Because commercially available IV iron formulations used in CKD meet the 
criteria for nanoparticles, their pharmacodynamic profile with regard to direct cell uptake and 
subsequent physiological effects needs to be better characterized for both RLDs and current and 
future generic formulations.
16,17
  
Pharmacokinetic evaluation of IV iron complexes is challenging, unless the compound can be 
directly measured (ferromagnetic) or is manufactured with a radiolabeled form of iron (
59
Fe) to 
distinguish the IV iron formulation from endogenous serum iron. While not well appreciated by 
clinicians, IV iron formulations exhibit zero-order or capacity-limited metabolism by the 
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reticuloendothelial system. This results in longer residence time in plasma with higher administered 
doses, especially with higher-molecular-weight formulations.
18
 This has potentially important 
implications regarding toxicity profiles, as doses administered beyond the reticuloendothelial system 
capacity limit will remain circulating in plasma for long periods of time until the concentration falls 
below the capacity limit, at which time the pharmacokinetic profile will become linear or 
concentration independent.  When the RLD Feraheme (ferumoxytol) was administered as two 510-
mg IV doses 24 h apart to healthy subjects, the metabolism did not appear to become linear until 
approximately 96 h after the first dose.
18
 Hillman et al. showed that radiolabeled iron–dextran 
exhibited capacity-limited metabolism at 500 mg, whereas the 250-mg dose appeared to have a linear 
pharmacokinetic profile.
19
 Ultimately, the complexity of IV iron–carbohydrate complex nanoparticle 
formulations has important implications with regard to both efficacy and safety in CKD. These agents 
have not been well studied with regard to comparative biodistribution, metabolic fate, or potential 
extracellular and intracellular toxicity profiles, and further evaluation of these agents is urgently 
needed, as long-term clinical use is widespread.  
Current regulatory guidance provides some recommendations for physicochemical 
characterization and pharmacokinetics of these agents. This is  especially relevant for abbreviated new 
drug applications for generic formulations, which necessitate independent clinical and translational 
studies to elucidate comparative product characteristics.
20
 Even slight changes (temperature, pH, 
polymer content) in the co-precipitation reaction to synthesize iron–carbohydrate nanoparticles can 
alter the properties of the final product, presenting challenges to reproducible manufacturing of IV 
iron formulations to be considered for generic approval.
21,22 
These formulations have been referred to 
as similars, as exact copies cannot be formulated.
11,21 
Although it has been shown that, if the iron 
complex is thermodynamically stable, complexes of similar molecular weight can be synthesized 
using multiple different manufacturing procedures, this may or may not translate to similar disposition 
in vivo.
23,24 
Simple fold dilutions in polymer content during iron oxide–dextran co-precipitation have 
yielded particles with similar hydrodynamic diameters determined by dynamic light scattering; 
however, the cellular iron uptake and cell viability are markedly different among the particles.
22
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Several ISSs available outside the United States have been shown to not meet United States 
Pharmacopeia (USP) Reference Standards.
10,11 
Differences in molecular weight, titratable alkalinity, 
and kinetics of degradation have also been shown between lots of the same generic formulation.
11,24
 
Toblli et al. characterized the physicochemical characteristics of the RLD Venofer and compared 
these to several of the compounds available and in clinical use in Europe and Asia.
11,25
 Notably, only 
one generic product in these comparative analyses complied with USP criteria. Differences in one or 
more of the criteria––pH, titratable alkalinity, and turbidity point––were observed in all generic 
products evaluated. Four of the seven products (57%) evaluated in one study
11
 had markedly higher 
molecular weights measured by gel-permeation chromatography. In animal studies using 40-mg/kg 
single IV doses, generic iron products have been shown to be associated with higher tissue 
concentrations of proinflammatory cytokines, higher intracellular antioxidant enzyme activity, 
adverse effects on the basic metabolic profiles (elevated liver function tests), and kidney dysfunction 
(elevated serum creatinine and proteinuria).
10,11,25–27
 It has been hypothesized that labile iron is 
principally involved with these observed deleterious effects by generating reactive oxygen species via 
the Fenton–Haber–Weiss reaction. In a systematic series of experiments, in vitro labile iron release 
profiles were evaluated for six IV iron formulations.
28
 The formulations studied included the only 
approved generic IV iron in the United States (sodium ferric gluconate complex) and the RLD 
Ferrlecit. Labile iron release in both saline and rat serum matrices was higher for the RLD versus 
the generic SFGC, indicative of some formulation variability.  To date, no published studies 
comparing RLDs with generic IV iron formulations have evaluated labile iron release profiles in 
human subjects.
10,11,25–27
 Because generic iron–carbohydrate complex formulations may differ with 
regard to molecular weight, carbohydrate shell chemistry, shell and particle diameter, and 
osmolality
13,14
 these agents require additional considerations for bioequivalence testing.
21
  
 
Adverse safety signals from in vitro, animal, and human studies: RLDs and iron–sucrose 
similars 
The hypothesis for the pathogenesis of acute oxidative stress induced by IV iron formulations is the 
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release of labile iron from the iron–carbohydrate structure resulting in transient concentrations of 
labile plasma iron and induction of the Fenton chemistry and the Haber–Weiss reaction, promoting 
formation of highly reactive free radicals, such as the hydroxyl radical.
29
 Labile plasma iron is the 
oxidative reactive fraction of non-transferrin-bound iron, iron that is not tightly bound transferrin. 
Among available RLD IV iron formulations, products with smaller carbohydrate shells are more 
labile and more likely to release labile iron directly into the plasma (i.e., before metabolism by RES) 
(Table 1).
30,31 
 The proposed biologic targets of labile iron–induced oxidative stress include nearly all 
systemic cellular components, including endothelial cells, myocardium, and liver, as well as low-
density-lipoprotein and other plasma proteins. Because of the extremely short half-lives of free 
radicals and the rapidity of the ensuing oxidative stress reactions produced by labile iron appearance, 
in vivo evaluation of this toxicity profile can only reasonably be accomplished by using biomarkers as 
surrogates. Recently, a systematic review of widely used biomarkers was conducted to assess 
oxidative stress in CKD. The authors applied scores for commonly used biomarkers for relationships 
to other biomarkers and clinical indicators, reliability, and characterization in the CKD literature.
32
 
Many of the identified “robust” biomarkers have been evaluated in the context of potential IV iron 
toxicity in CKD (malondialdehyde, protein carbonyl, and F2-isoprostane); however, it should be 
noted that none of the identified biomarkers have specificity for iron-induced oxidative stress.
33,34
 An 
additional concern regarding appearance of labile plasma iron is the potential for easily accessible 
iron to impair innate immunity and augment bacterial growth, increasing the risk of infection.
35
  
IV iron formulations have clearly been shown to induce oxidative stress, inflammation, and 
cellular toxicity in cell culture models, animal models, and acutely in human subjects.
10–12,30,34
 
Differential toxicity profiles have been observed among the available IV iron products in vitro, with 
more labile compounds inducing more toxicity than compounds with larger carbohydrate shells that 
exhibit better stability.
35,36
  In animal models, similar observations have been reported with 
administration of IV iron compounds inducing labile iron appearance, pro-oxidant cell signaling, 
tissue inflammation, cellular iron deposition, and cytotoxicity.
10,32,37,38
 IV iron has also been 
associated with immune dysfunction and increased Gram-positive bacteria growth in vitro.
11,36,39
 In 
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some studies, a similar rank order for toxicity (labile products > stable products) has been 
demonstrated;
35
 however, other studies have shown greater cellular iron staining and tissue 
inflammation with higher-molecular-weight products.
11 
In similar rat models, increased tissue 
oxidative stress has been observed with several ISS (i.e., generic) products compared with the branded 
product.
10
 A caveat to interpretation of these in vivo animal model data is the wide variation in doses 
administered in the experiments (1.4 mg/kg to 500 mg/kg).
10,31,37 
 While the dose in the rat should be 
higher on the basis of allometric scaling, the optimal dose to model human IV iron toxicity has not 
been determined.  
Although the biological plausibility and available in vitro and animal model data are 
generally compelling, controversy remains regarding whether iron-induced oxidative stress 
manifests long-term toxicity, such as cardiovascular disease and infection, in CKD patients.  
The complex biochemical milieu in CKD, in tandem with the multiple inciting factors for 
oxidative stress and inflammation, complicates investigation of potential IV iron safety 
concerns. Epidemiologic analyses conducted with dialysis patient data in the late 1990s 
demonstrated positive correlations between the number of IV iron vials billed and mortality.
40
 
Given that the impact of iron-induced oxidative stress on cardiovascular disease likely takes 
extended periods of time, immediate correlation of iron dose to cardiovascular events is not 
likely possible. In later analyses with newer data, application of more sophisticated statistical 
analyses with incorporation of lag times to adjust for time-varying confounders found that the 
relationship between IV iron and cardiovascular outcomes was not statistically significant.
41
 
A recent analysis evaluated short-term cardiovascular risk associated with IV iron dosing 
practices (bolus vs. maintenance and high dose vs. low dose).
42
 Large-dose strategies (bolus 
and high dose) were not associated with increased risk of cardiovascular death, 
hospitalization for myocardial infarction, hospitalization for stroke, or any 
composite/combination of any of these three.
42
 Evaluating the relationship between iron and 
infection risk could be more easily evaluable, given that the presumed risk of infection would 
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likely be in close proximity to the dose administered when labile iron is presumably present. 
In a small retrospective study, 132 dialysis patients receiving their first course of IV iron 
were followed for 1 year after therapy initiation for time to first bacteremia episode.
43
 
Patients with transferrin saturation values ≥ 20% and ferritin ≥ 100 were defined as iron 
replete, and this group had 2.5-fold higher risk of bacteremia compared with patients with 
functional iron deficiency and those who were iron deficient.
43
 These data may suggest that 
iron availability is increased when additional iron is administered to these iron-replete 
patients, promoting bacterial growth and subsequent bloodstream infections. More recently, a 
large epidemiologic study examined the risk of infection-related hospitalization with bolus 
versus maintenance or high versus low IV iron–dosing patterns.44 Bolus dosing of IV iron 
was associated with a higher risk of infection-related hospitalization (25 additional events per 
1000 patient-years) and increased risk of mortality. Differences in infection rates between 
iron formulations have been less clear. In two studies evaluating U.S. Renal Data System 
data, short-term infection risk in hemodialysis patients with sodium ferric gluconate was 
marginally lower than iron sucrose.
45
 In contrast, longer-term infection risk was modestly 
lower in iron–sucrose–treated hemodialysis patients.46 Prospective studies are needed to 
elucidate whether risk and predictors of infection differ among formulations. 
In interventional clinical trials and observational reports, when compared to the RLD, 
different formulations and lots of ISS have been associated with intracellular reactive oxygen species 
generation, increases in biomarkers of endothelial dysfunction, and adverse drug events, including 
hypotension and phlebitis.
12,26,47,48 
 Labile iron release in the immediate postadministration period 
(directly from the formulation) from RLD iron–carbohydrate complexes has been shown to induce 
oxidative stress, cytokine activation, and endothelial dysfunction.
12,30,49
 Therefore, the biologic 
plausibility strongly implies that differences in labile iron release are fundamentally responsible for 
the higher rates of adverse drug events reported with generic iron–sucrose formulations. Table 2 
summarizes published studies evaluating RLDs and ISS products across the translational research 
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spectrum. 
 
Formulation-based labile iron release is a viable and pragmatic parameter for enhancing BE 
evaluation of generic IV iron products  
As discussed, the biologic plausibility of labile iron being a fundamental cause of adverse drug events 
(excluding immunogenetic reactions) related to IV iron formulations is strong and supported by 
translational research evaluating several of the RLD products.
24,48 
The higher incidence of hypotension 
reported with some generic formulations, including different lots of the same formulation, is likely 
attributable to formulation-based free iron release.
24,48
 Thus, labile iron measurement is a both a 
relevant and practical candidate to further evaluate BE of generic IV iron formulations.
29,49,50
 
Assessment of labile iron–release profiles extends data provided by physicochemical characterization 
(PCC) to better understand how the disposition of generic formulation compares to the RLD. As 
mentioned previously, despite evidence of similar PCC, these complex formulations may behave 
differently in in vivo systems.
51
 This underscores the need for a multipronged approach in evaluation 
of BE among complex drug formulations. Animal studies evaluating generic iron sucrose 
formulations have evaluated serum iron concentrations and transferrin saturation (TSAT) and found 
values to be higher in animals receiving the generic formulations versus the RLD.
10,11,25–27 
However, 
TSAT is not a direct measurement of the reactive labile iron species and does not adequately represent 
the potential for deleterious redox reactions. Although TSAT values greater than 100% strongly infer 
the presence of labile iron, we and others have shown that labile iron is present at TSAT values less 
than 100%, limiting the utility of this parameter.
30,52
 An optimal approach for BE for generic IV iron 
formulations would be development of an in vitro to in vivo correlation (IVIVC) model. A validated 
IVIVC model would allow in vitro labile iron–release kinetics under physiologically relevant 
conditions to support BE evaluation in addition to rigorous PCC with standards.
50,53
 Several assays 
have been developed and validated to measure labile plasma iron, mainly employing redox-active or 
chelatable methodologies; however, many of these assays are not viable for in vitro determination of 
labile iron release from the formulation.
28,29
 Jahn et al. used the Ferrozine assay to determine iron 
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release among six available IV iron formulations in vitro incubated in human serum.
14
 Lower-
molecular-weight formulations and higher concentrations representing clinically relevant doses were 
associated with higher concentrations of iron release. However, it should be noted that this assay 
measures non-transferrin-bound iron (labile reactive iron plus iron weakly bound to other plasma 
proteins) and may overestimate formulation-based labile iron release.   
The difficulties in evaluating non-biologic complex drugs, such as IV iron 
formulations, is appreciated by scientists and regulatory agencies.
53,54 
However, most 
clinicians who use these formulations across a wide spectrum of acute and chronic disease 
states are not aware of their complicated pharmacokinetic and pharmacodynamic profiles, nor 
do they appreciate the challenges in BE evaluation of generic formulations. A survey 
administered to 140 pharmacists in France and Spain was designed to provide insight into the 
current decision-making process for pharmacists regarding IV iron products in the hospital.
55 
Substitution of RLD iron–sucrose for an ISS ranged from 38–47%. However, only 19% and 
7% of pharmacists in France and Spain, respectively, thought there were relevant differences 
between RLD and ISS formulations.  
Taken collectively, there is a need for comprehensive clinical and translation 
investigations of IV iron formulations to mechanistically evaluate and understand the 
biodistribution, safety, and toxicity profiles of these agents.  Such studies would be useful in 
moving the needle forward on BE evaluation to ensure safe and effective generic IV iron 
products. 
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Table 1. Comparison of physicochemical characteristics and pharmacokinetics of reference 
listed drug IV iron formulations 
PROPERTIES Feraheme Injectafer InFed Venofer Ferrlecit 
MW (Da) 731,000 150,000
 
 410,000  252,000
 
200,000 
Carbohydrate 
shell 
 
Polyglucose 
sorbitol 
carboxymethylether
 
Carboxymaltose 
Detran 
polysaccharide 
Sucrose 
Gluconate, 
loosely 
associated 
sucrose 
Median shell/ 
particle 
diameter (nm)
 
26.3 23.1 12.2
 
8.3
 
8.6
 
Relative labile 
Fe release 
 + + ++ +++ +++ 
Relative 
stability of 
elemental Fe 
within the 
CHO Shell 
 
High High High Medium Low 
Relative 
osmolalities  
Isotonic Isotonic Isotonic Hypertonic Hypertonic 
Administratio
n (IV push) 
30 mg/sec Bolus push 
50 mg (1 mL)/ 
min 
~20 
mg/min 
12.5 
mg/min 
  
 
This article is protected by copyright. All rights reserved. 
 
16 
rates  
Half-life (hrs)
 ~ 15 7–12 5–20 6 ~ 1 
IV, intravenous; CHO, carbohydrate. 
 
 
 
Table 2. Summary of in vitro, animal and human subject studies comparing iron–sucrose 
similars (ISSs) to the RLD Venofer 
Author Formulations studied Study design Key findings 
In vitro  
Kuo et al.
12
  ISS (Nan-Kuang 
Pharmaceuticals) vs. 
control 
Human aortic 
endothelial cells 
(HAECs) and 
monocytes (U937) 
incubated with ISS 40–
160 g/mL for 4 hours. 
Time-dependent 
intracellular iron 
uptake, ROS 
generation, NADPH 
oxidase (NOX) 
activity, VCAM-1, 
ICAM-1, increased 
NF-B in HAECS, and 
endothelial–monocyte 
adhesion highest in 
ISS-treated cells 
In vivo animal 
Toblli et al.
26
  Venofer, ISS test 1,
a
 ISS 
test 2,
a
 control 
Single 40 mg/kg IV 
injection in rats. Serum 
and tissue samples 
collected at 24 h, and 7 
and 28 days. 
Higher tissue iron 
deposition, antioxidant 
enzyme, and cytokine 
generation with both 
ISS formulations vs. 
RLD and control 
observed at 24 h and 
day 7. No difference at 
day 28. 
Toblli et al.
11
  Venofer, six ISS 
formulations sourced 
from Pakistan, India, and 
Taiwan 
Rats randomly 
allocated to receive 40 
mg/kg IV of an IV iron 
formulation or saline at 
days 0, 7, 14, 21, and 
28. Serum collected at 
day 1, 8, 15, 22, and 
29.  Tissue samples 
collected at day 29. 
Higher serum iron, 
TSAT observed at days 
1, 8, and 29 with all 
ISS formulations vs. 
RLD and control. 
Higher tissue iron 
deposition observed 
with ISS
b
 vs. RLD and 
control; higher tissue 
cytokines (TNF-, IL-
6) with ISS 
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formulations 
Kuo et al.
12
  ISS (Nan-Kuang 
Pharmaceuticals) vs. 
control 
Mice (C57BL/6) mice 
were established in 
four groups: sham with 
saline, sham with ISS, 
uninephrectomy (SNx) 
with saline, and SNx 
with iron to evaluate 
vascular adhesion. A 
second group of ApoE
–
/–
 mice was established 
in the same four groups 
to evaluate 
atherogenesis. Doses of 
ISS were administered 
IP at 2 mg/25 g body 
weight for 5 days.  
SNx wild-type mice 
treated with iron had 
the highest amount of 
leukocyte adherence to 
aortic endothelium 
compared to sham   
iron. SNx not treated 
with iron had higher 
amounts of leukocyte 
adherence vs. sham   
iron. ROS were highest 
in SNx + iron mice, as 
was VCAM-1 and 
ICAM-1 expression in 
aortic tissue. ROS 
generation appeared to 
be mediated by NOX, 
confirmed by p22
phox
 
expression in the aortic 
endothelium as well as 
the medial layer 
Toblli et al.
27
 2015 Eight ISS sourced from 
Europe and Asia vs. 
three different lots of 
Venofer and control 
Rats were administered 
40 mg/kg of Venofer or 
one of eight ISSs 
adjusted for weekly 
body weight and 
diluted in saline to a 
final volume of 1 mL at 
days 0, 7, 14, 21, and 
28. Blood samples 
were collected at 24 h 
and 29 days. Tissue 
samples were collected 
at day 29. 
Transferrin saturation 
at end of study was 
significantly higher 
with all ISSs vs 
Venofer and control. 
All formulations had 
significant tissue 
deposition in liver, 
heart, and kidney vs. 
control. One 
formulation of Venofer 
showed highest values 
for ferritin 
immunostaining in the 
liver. All ISS 
formulations had 
significantly higher IL-
6 immunostaining vs. 
all three lots of 
Venofer. 
Spicher et al.
56 
Three approved IV iron 
formulations (Venofer, 
Ferrlecit, Ferinject) and 
one ISS (FerMed, 
Medice Arzneimittel 
ISS and Venoferwere 
administered at 200 
and 400 g into 
chicken chorioallantoic 
No significant 
difference in liver or 
heart tissue deposition 
was observed between 
ISS and RLD.  
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Pütter GmbH & Co. KG) membranes.  
Humans 
Rottembourg et al.
57 
Venofer and ISS 
(Mylan SAS, Saint 
Priest, France 
manufactured by Help 
SA Pharmaceuticals, 
Athens, Greece) 
Retrospective study of 
pre–post ISS switch in 
hemodialysis patients 
(n = 75). 
IV iron doses, ESA 
doses and total drug 
costs increased and 
hemoglobin transiently 
decreased post switch 
to ISS.  
Lee et al.
24
  RLD Venoferrum vs. 
ISS Ferex 
(SejongPharmas, South 
Korea) 
Retrospective study of 
postpartum patients 
who received 
Venoferrum (200 
mg/100 mL NS), ISS 
(200 mg/100 mL NS), 
and ISS (200 mg/200 
mL NS). n = 658. 
Adverse events 
reported were 
significantly lower with 
Venoferrum. Injection-
site reactions and 
phlebitis were 
significantly higher in 
ISS-treated patients, 
especially with greater 
dilution of ISS.  
Stein et al.
48
  ISS (FerMed, Medice 
Arzneimittel Pütter 
GmbH & Co. KG) 
Case series of three 
patients receiving ISS 
who previously 
tolerated Venofer 
(300 mg/300 mL over 
1.5 h). 
All three patients 
experienced adverse 
drug reactions, 
including urticaria, 
headache, and 
peripheral edema.  
Kuo et al.
12
  ISS (Nan-Kuang 
Pharmaceutical) vs. 
control  
CKD stage 5 patients 
(n = 40) were randomly 
allocated to receive ISS 
(100 mg/250 mL) or 
NS 250 mL 
administered for 60 
min postdialysis for 10 
weeks. Blood samples 
were collected every 2 
weeks. Healthy 
subjects (n = 20) had 
blood collected once. 
CKD stage 5 subjects 
receiving ISS had 
highest ROS 
production, soluble 
adhesion molecule 
concentrations (ICAM-
1, VCAM-1), and ex 
vivo monocyte–
endothelial adhesion. 
Aguera et al.
58
  ISS and RLD 
(manufacturers not 
supplied) 
Prospective study after 
institutional switch to 
RLD from ISS (n = 
342) 
Reduced IV iron and 
ESA doses required 
during prospective 
RLD observation 
period. Hemoglobin 
remained stable. 
a
Manufacturer not provided. 
b
Except ISSFERP (Ferplex) in liver. VCAM-1, vascular cell adhesion 
molecule; ICAM-1, intracellular adhesion molecule; NF-B, nuclear factor  light-chain enhancer of 
activated B cells; IP, intraperitoneal; ROS, reactive oxygen species. 
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